Mankind Pharma Ltd (MANKIND) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Mankind Pharma Ltd on NSE and BSE, with an AI summary of each filing.
Intimation of participation in the Investor Conference.
Intimation · 03 Nov 2026, 11:14 pm
Mankind Pharma to Participate in Ashika Stock Services Investor Conference Mankind Pharma Limited announced that its management will participate in an investor conference hosted by Ashika Stock Services Limited on 5th Nov'26 in Mumbai. The event will include one-on-one and group meetings. The company stated that discussions will strictly focus on general business outlook and publicly available information, ensuring no unpublished price sensitive information (UPSI) is shared during the interactions.
Please find attached transcript of the Earnings Conference Call for Q2 & H1 FY27
Transcript · 30 Oct 2026, 8:46 pm
Please find attached intimation regarding re-affirmation/withdrawl of Credit Rating by CRISIL
Others (Uncategorized) · 30 Oct 2026, 1:56 am
CRISIL Reaffirms and Withdraws Key Debt Ratings for Mankind Pharma On 29th Oct'26, CRISIL Ratings reaffirmed its 'CRISIL AA+/Stable' rating on Mankind Pharma Limited’s Non-Convertible Debentures (NCDs) worth ₹400 crore and ₹2,100 crore. Simultaneously, the agency withdrew its 'CRISIL AA+/Stable' rating on NCDs amounting to ₹2,500 crore and its 'CRISIL A1+' rating on Commercial Paper totaling ₹1,500 crore.
In continuation of our earlier intimation dated October 22, 2026 please find attached the Investor Presentation to be made during the said Analyst / Institutional Investors meet
Investor Presentation · 27 Oct 2026, 10:44 pm
Mankind Pharma Targets Chronic Shift, BSV Scale-Up, and CAR-T Biopharma Entry Mankind Pharma reported FY26 revenue of ₹14,278 Cr, posting an 18.1% CAGR over FY21–26. As of Q2 FY27, volume growth reached 6.2% versus IPM's 5.2%. The company aims to expand its chronic portfolio from ~39% to ~50% of sales by FY30E and scale hospital sales to ~5%. Outstanding debt fell ~75% from peak levels to ~₹2,500 Cr, with full repayment targeted by 2028. Additionally, Mankind acquired a 70% stake in Belgium-based Armed Cell Therapeutics for €48 Mn to advance in-vivo CAR-T oncology candidates.
Please find attached link for audio recording of the Investor Conference Call held on October 26, 2026
Audio / Video · 27 Oct 2026, 1:20 am
Mankind Pharma Releases Audio Recording for Q2 and H1 FY27 Earnings Call Mankind Pharma Limited has informed stock exchanges that the audio recording of its earnings conference call for Q2 and H1 FY27, conducted on 26th Oct'26, is now accessible via an online link. The disclosure was submitted in compliance with Regulations 30 and 51 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, following previous intimations regarding the scheduling and rescheduling of the investor call.
Investor Presentation on Financial Results of the Company for Q2 & H1FY27
Investor Presentation · 26 Oct 2026, 8:58 pm
Mankind Pharma Reports Robust Q2 FY27 Results with Strong Margin Expansion Mankind Pharma reported Q2 FY27 revenue of INR 4,338 Cr, up 17.3% YoY, driven by a 14.8% increase in domestic business to INR 3,657 Cr and a 32.7% rise in exports to INR 681 Cr. EBITDA grew 27.2% YoY to INR 1,175 Cr as EBITDA margin expanded 210 bps to 27.1%. PAT surged 37.7% YoY to INR 716 Cr with a 16.5% margin. Net debt stood at INR 2,639 Cr (0.6x Adj. EBITDA). The company entered next-gen CAR-T therapies via an ACTx acquisition.
Press release on financial results Q2&H1FY27
Press Release · 26 Oct 2026, 8:56 pm
Mankind Pharma Reports Strong Q2 FY27 With PAT Up 37.7% YoY Mankind Pharma reported a 17.3% YoY rise in consolidated revenue to INR 4,338 Cr for Q2 FY27, supported by a 14.8% increase in domestic revenue to INR 3,657 Cr and a 32.7% surge in exports to INR 681 Cr. EBITDA grew 27.2% YoY to INR 1,175 Cr with margins expanding 210 bps to 27.1%, while PAT jumped 37.7% YoY to INR 716 Cr. H1 FY27 revenue reached INR 8,368 Cr, up 15.1% YoY, with PAT at INR 1,290 Cr. Growth was driven by outperformance in chronic and acute domestic portfolios.
Scheme of arrangement for amalgamation of Prolijune Lifescinces Private Limited (WOS) with Mankind Pharma Limited
Others (Uncategorized) · 26 Oct 2026, 8:54 pm
Mankind Pharma Approves Wholly Owned Subsidiary Amalgamation and Reports Q2 Financials Mankind Pharma approved the amalgamation of wholly owned subsidiaries Prolijune Lifesciences and Pavi Buildwell into the parent entity, with an appointed date of 1st Apr'27, involving no share issuance or cash consideration. For Q2 ended 30th Sep'26, consolidated revenue from operations grew 17.3% YoY to ₹4,337.86 crore, while consolidated profit after tax rose 37.7% YoY to ₹716.12 crore. Separately, the board noted the merger of step-down subsidiary Upakarma Ayurveda into Mankind Consumer Products to optimize operations and strengthen direct-to-consumer capabilities.
Scheme of arrangement for amalgamation of Pavi Buildwell Private Limited (WOS) with Mankind Pharma Limited
Others (Uncategorized) · 26 Oct 2026, 8:51 pm
Mankind Pharma Approves Amalgamation of Wholly Owned Subsidiaries and Reports Q2 Financials Mankind Pharma approved the Scheme of Arrangement for the amalgamation of wholly owned subsidiaries Prolijune Lifesciences and Pavi Buildwell into the company, effective 1st Apr'27, with no new share issuances or cash consideration. The board also noted the merger of Upakarma Ayurveda into Mankind Consumer Products. For Q2 ended 30th Sep'26, consolidated revenue from operations rose 17.33% YoY to ₹4,337.86 crore, while net profit grew 37.67% YoY to ₹716.12 crore. Separately, the board approved raising its investment limit in its Netherlands arm to €50mn to acquire a 70% stake in ACTx.
Assets cover certificate for the quarter and half year ended 30th September 2026
Others (Uncategorized) · 26 Oct 2026, 8:47 pm
Mankind Pharma Q2 FY27 Financial Results and Corporate Restructuring Summary Mankind Pharma reported consolidated revenue from operations of ₹4,337.86 Cr for the quarter ended 30th Sep'26, up 17.33% YoY from ₹3,697.16 Cr. Consolidated net profit rose 37.67% YoY to ₹716.12 Cr compared to ₹520.18 Cr. For H1 FY27, consolidated revenue reached ₹8,368.45 Cr with net profit at ₹1,290.21 Cr. The Board approved the merger of wholly owned subsidiaries Prolijune Lifesciences and Pavi Buildwell into Mankind Pharma with an appointed date of 1st Apr'27, involving no share issuance or cash outflow.
Outcome of Board Meeting
Outcome · 26 Oct 2026, 8:44 pm
Results for the Quarter and Half year ended 30th September 2026.
Financial Result · 26 Oct 2026, 8:41 pm
Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 26 Oct 2026, 8:37 pm
Mankind Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 4,338 (+17.3% YoY | +7.6% QoQ) ■ EBITDA: 1,171 (+27.1% YoY | +10.9% QoQ) ■ EBITDA Margin (%): 27.0 (+208 bps YoY | +80 bps QoQ) ■ PAT: 711 (+39.1% YoY | +25.2% QoQ) ■ EPS (INR): 17.2 (+38.9% YoY | +25.2% QoQ)
Due to a technical issue, the meeting link provided in the earlier intimation regarding "Rescheduling of the Earnings Conference Call for Q2 & H1 FY27", uploaded today at 15:39:16 IST, ....
Intimation · 23 Oct 2026, 12:21 am
Mankind Pharma Reschedules Q2 & H1 FY27 Earnings Call to 26th Oct'26 Mankind Pharma Limited has advanced its Q2 & H1 FY27 earnings conference call originally scheduled for 26th Oct'26 at 06:00 PM IST to 05:00 PM IST on the same date. The company re-submitted the intimation to provide an updated, accessible meeting link after encountering technical issues with the link in its previous filing. All other terms and details regarding the earnings call remain unchanged.
Please find attached Intimation regarding Schedule of Analyst/ Institutional Investors Meet
Intimation · 22 Oct 2026, 9:28 pm
Mankind Pharma Schedules Analyst and Institutional Investors Meet Mankind Pharma Limited will host an in-person group Analyst/Institutional Investors' Meet on 27th Oct'26 in Mumbai. The company’s senior management, alongside members of the leadership team from Armed Cell Therapeutics (ACTx), will represent the firm at the interaction.
Please find attached intimation regarding rescheduling of Earnings Conference Call for Q2 & H1 FY27
Intimation · 22 Oct 2026, 9:09 pm
Mankind Pharma Reschedules Q2 & H1 FY27 Earnings Conference Call to 26th Oct'26 Mankind Pharma Limited has rescheduled its Earnings Conference Call for Q2 & H1 FY27 to Monday, 26th Oct'26, at 05:00 PM IST, advancing it from the earlier scheduled time of 06:00 PM IST on the same date. The company confirmed that all other previously communicated details regarding the earnings call remain unchanged.
Intimation regarding payment of interest and redemption of Non-Convertible Debentures ("NCD")
Others (Uncategorized) · 16 Oct 2026, 10:34 pm
Mankind Pharma Completes NCD Redemption and Interest Payments Mankind Pharma paid half-yearly interest and fully redeemed its matured NCDs on 16th Oct'26. The company completed the full redemption of 125,000 NCDs (ISIN: INE634S07025) worth ₹1,250 crore upon maturity, leaving zero outstanding amount for the tranche. It disbursed gross interest of ₹50.07 crore (net ₹49.97 crore) for ISIN INE634S07025 and gross interest of ₹99.90 crore (net ₹99.86 crore) on its ₹2,500 crore issue (ISIN: INE634S07033). All payments were executed on schedule.
Please find attached intimation regarding ESG Rating
Others (Uncategorized) · 16 Oct 2026, 2:08 am
Mankind Pharma Assigned ESG Rating of 71 by NSE Sustainability for FY26 Mankind Pharma Limited has been assigned an Environmental, Social, and Governance (ESG) rating of '71' by NSE Sustainability Ratings and Analytics Limited for FY26. The rating was independently assigned by the SEBI-registered ESG rating provider based on publicly available information, without direct engagement from the company.
Please find attached press release titled "Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies".
Press Release · 16 Oct 2026, 1:01 am
Mankind Pharma Acquires 70% Stake in Armed Cell Therapeutics for EUR 48Mn Mankind Pharma approved acquiring a 70% majority stake in Belgium-based Armed Cell Therapeutics B.V. (ACTx) for EUR 48Mn in cash instalments via its wholly owned subsidiary, Mankind Pharma (Netherlands) B.V. To fund this, Mankind raised its investment limit in the Netherlands arm by EUR 45Mn to EUR 50Mn on 15th Oct'26. ACTx develops next-generation CAR-T cancer therapies, with lead programs targeting non-Hodgkin lymphoma and small cell lung cancer. The transaction marks Mankind's strategic entry into global, innovation-led oncology cell therapies.
Please find attached intimation regarding investment by the Company.
Others (Uncategorized) · 16 Oct 2026, 12:57 am
Mankind Pharma Acquires 70% Stake in Armed Cell Therapeutics for EUR 48Mn Mankind Pharma approved an additional investment of up to EUR 45Mn into wholly owned subsidiary Mankind Pharma (Netherlands) B.V. on 15th Oct'26, raising its total investment limit to EUR 50Mn. The subsidiary will utilize EUR 48Mn in cash instalments to acquire a 70% majority stake in Belgium-based Armed Cell Therapeutics B.V. (ACTx). ACTx specializes in next-generation CAR-T cancer therapies, focusing on non-Hodgkin lymphoma and small cell lung cancer. The transaction marks Mankind's strategic expansion into global, innovation-led oncology biopharmaceuticals.
Please find attached outcome of Board Meeting held on October 15, 2026.
Others (Uncategorized) · 16 Oct 2026, 12:53 am
Mankind Pharma Approves Acquisition of 70% Stake in Armed Cell Therapeutics Mankind Pharma approved an additional investment of up to EUR 45Mn in wholly owned subsidiary Mankind Pharma (Netherlands) B.V., raising its investment limit to EUR 50Mn. The subsidiary will acquire a 70% stake in Belgium-based biotech Armed Cell Therapeutics B.V. (ACTx) via an all-cash consideration of EUR 48Mn payable in instalments. ACTx develops next-generation CAR-T cancer therapies, with lead clinical programs targeting non-Hodgkin lymphoma and small cell lung cancer. This strategic transaction marks Mankind's entry into advanced oncology cell therapies.
Please find attached intimation regarding Earnings Conference Call for Q2 & H1 FY27.
Intimation · 26 Oct 2026, 6:00 pm
Mankind Pharma Schedules Q2 and H1 FY27 Earnings Call on 26th Oct'26 Mankind Pharma Limited has scheduled its earnings conference call on Monday, 26th Oct'26, at 06:00 PM IST. The management will host the call to discuss the company's financial and business performance for Q2 & H1 FY27.
MANKIND PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 26-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 26 Oct 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 26 Oct 2026, 5:30 am
Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2026 ,inter alia, to consider and approve the unaudited standalon and ....
Intimation · 26 Oct 2026, 5:30 am
Mankind Pharma Schedules Board Meeting for Q2 FY27 Financial Results Mankind Pharma Limited has scheduled its Board of Directors meeting for 26th Oct'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. Additionally, the trading window for dealing in company securities remains closed for designated insiders until 28th Oct'26, in compliance with SEBI insider trading regulations.